Eli Lilly and’s (LLY) “Buy” Rating Reaffirmed at Leerink Swann
LLY has been the subject of several other research reports. BMO Capital Markets reaffirmed a buy rating and set a $94.00 target price on shares of Eli Lilly and in a research note on Monday, October 3rd. JPMorgan Chase & Co. raised shares of Eli Lilly and from a neutral rating to an overweight rating and increased their target price for the stock from $92.00 to $95.00 in a research note on Thursday, September 8th. Zacks Investment Research lowered shares of Eli Lilly and from a buy rating to a hold rating in a research note on Wednesday. Jefferies Group reaffirmed a buy rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Wednesday, September 14th. Finally, SunTrust Banks Inc. reaffirmed a buy rating on shares of Eli Lilly and in a research note on Wednesday, June 15th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $97.06.
Eli Lilly and (NYSE:LLY) opened at 82.09 on Friday. The company’s 50 day moving average is $79.44 and its 200 day moving average is $77.49. The company has a market cap of $86.83 billion, a price-to-earnings ratio of 35.38 and a beta of 0.17. Eli Lilly and has a 1-year low of $67.88 and a 1-year high of $88.16.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same quarter in the prior year, the firm posted $0.90 earnings per share. Eli Lilly and’s quarterly revenue was up 8.6% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and will post $3.59 EPS for the current year.
In related news, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the transaction, the insider now owns 1,300 shares of the company’s stock, valued at approximately $108,108. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Iowa State Bank purchased a new position in shares of Eli Lilly and during the second quarter valued at $104,000. PineBridge Investments L.P. increased its position in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC bought a new position in Eli Lilly and during the second quarter worth approximately $117,000. Coconut Grove Bank increased its position in Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. increased its position in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares in the last quarter. 74.96% of the stock is owned by hedge funds and other institutional investors.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.